APSAC is an anisoylated human plasminogen-streptokinase complex useful in the
treatment of myocardial infarct. Its reported advantages over other existing thrombolytics
such as alteplase and streptokinase include a longer half life, ease of administration, and a
more specific local antithrombotic effect.
